Experienced in Essential Thrombocythemia

Dr. Alexander N. Starodub

Hematology Oncology | Oncology | Hematology
Christ Hospital Medical Specialists Ii, LLC
2139 Auburn Ave, 
Cincinnati, OH 
Clinical Trials:Currently Recruiting for 1 Trial
Accepting New Patients
Experienced in Essential Thrombocythemia
Christ Hospital Medical Specialists Ii, LLC
2139 Auburn Ave, 
Cincinnati, OH 
OverviewInsuranceLocationsClinical Research

Overview

Alexander Starodub is a Hematologist Oncology specialist and an Oncologist in Cincinnati, Ohio. Dr. Starodub and is rated as an Experienced provider by MediFind in the treatment of Essential Thrombocythemia. His top areas of expertise are Colorectal Cancer, Familial Colorectal Cancer, Pancreatic Cancer, Pleuropulmonary Blastoma, and Bone Marrow Aspiration. Dr. Starodub is currently accepting new patients.

His clinical research consists of co-authoring 21 peer reviewed articles and participating in 12 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology Oncology
Oncology
Hematology
Licenses
Internal Medicine in OH
Hospital Affiliations
Riverside Regional Medical Center
Christ Hospital
Languages Spoken
English
Gender
Male

Insurance

Please contact the provider to confirm they accept your insurance or if you don't see your insurance listed.

Accepted insurance plans

  •  Medical Health
  •  CareSource
  •  Humana
  •  Piedmont

Locations

CHRIST HOSPITAL MEDICAL SPECIALISTS II, LLC
2139 Auburn Ave, Cincinnati, OH 45219
Other Locations
CHRIST HOSPITAL MEDICAL SPECIALISTS II, LLC
1955 Dixie Hwy, Suite G, Fort Wright, KY 41011

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

12 Clinical Trials

(CompassHER2-pCR): Preoperative THP and Postoperative HP in Patients Who Achieve a Pathologic Complete Response
(CompassHER2-pCR): Preoperative THP and Postoperative HP in Patients Who Achieve a Pathologic Complete Response
Enrollment Status: Recruiting
Publish Date: April 18, 2024
Intervention Type: Procedure, Biological, Drug, Radiation
Study Drugs: Docetaxel, Nab-Paclitaxel, Paclitaxel, Pertuzumab, Trastuzumab, Trastuzumab Emtansine
Study Phase: Phase 2
A Phase 1b, Open-Label, Dose-Escalation, Dose-Expansion Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Orally Administered SM08502 Combined With Hormonal Therapy or Chemotherapy in Subjects With Advanced Solid Tumors
A Phase 1b, Open-Label, Dose-Escalation, Dose-Expansion Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Orally Administered SM08502 Combined With Hormonal Therapy or Chemotherapy in Subjects With Advanced Solid Tumors
Enrollment Status: Terminated
Publish Date: August 09, 2024
Intervention Type: Drug
Study Drugs: SM08502, Abiraterone, Prednisone, Docetaxel, FOLFIRI Protocol, Panitumumab
Study Phase: Phase 1
An Open-Label, Randomized, Multicenter Study Evaluating the Activity of Lasofoxifene Relative to Fulvestrant for the Treatment of Pre- and Postmenopausal Women With Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation
An Open-Label, Randomized, Multicenter Study Evaluating the Activity of Lasofoxifene Relative to Fulvestrant for the Treatment of Pre- and Postmenopausal Women With Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation
Enrollment Status: Active_not_recruiting
Publish Date: April 18, 2024
Intervention Type: Drug
Study Drugs: Lasofoxifene, Fulvestrant
Study Phase: Phase 2
A Phase I/II Study of Once or Twice Weekly IMMU-130 (hMN-14-SN38, Antibody-Drug Conjugate) in Patients With Colorectal Cancer
A Phase I/II Study of Once or Twice Weekly IMMU-130 (hMN-14-SN38, Antibody-Drug Conjugate) in Patients With Colorectal Cancer
Enrollment Status: Terminated
Publish Date: January 24, 2024
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
A Phase 2/3, Randomized, Open-Label Study of Maintenance GRT-C901/GRT-R902, A Neoantigen Vaccine, in Combination With Immune Checkpoint Blockade for Patients With Metastatic Colorectal Cancer
A Phase 2/3, Randomized, Open-Label Study of Maintenance GRT-C901/GRT-R902, A Neoantigen Vaccine, in Combination With Immune Checkpoint Blockade for Patients With Metastatic Colorectal Cancer
Enrollment Status: Active_not_recruiting
Publish Date: December 22, 2023
Intervention Type: Drug
Study Phase: Phase 2/Phase 3
An Open Label, Escalating Multiple Dose Study to Evaluate the Safety, Toxicity, Pharmacokinetics, and Preliminary Activity of BTX-1188 in Subjects With Advanced Malignancies
An Open Label, Escalating Multiple Dose Study to Evaluate the Safety, Toxicity, Pharmacokinetics, and Preliminary Activity of BTX-1188 in Subjects With Advanced Malignancies
Enrollment Status: Terminated
Publish Date: September 18, 2023
Intervention Type: Drug
Study Phase: Phase 1
A Phase 1 Dose Escalation With Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMV564 Alone and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors
A Phase 1 Dose Escalation With Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMV564 Alone and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors
Enrollment Status: Unknown
Publish Date: October 19, 2021
Intervention Type: Biological
Study Phase: Phase 1
A Phase I/II Study of IMMU-132 (hRS7-SN38 Antibody Drug Conjugate) in Patients With Epithelial Cancer
A Phase I/II Study of IMMU-132 (hRS7-SN38 Antibody Drug Conjugate) in Patients With Epithelial Cancer
Enrollment Status: Completed
Publish Date: August 12, 2021
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GS-5745 as Monotherapy and in Combination With Chemotherapy in Subjects With Advanced Solid Tumors
A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GS-5745 as Monotherapy and in Combination With Chemotherapy in Subjects With Advanced Solid Tumors
Enrollment Status: Completed
Publish Date: June 02, 2020
Intervention Type: Drug
Study Phase: Phase 1
A Phase l/ll Dose Escalation and Cohort Expansion Study of the Safety, Tolerability and Efficacy of Anti-CD27 Antibody (Varlilumab) Administered in Combination With Anti-PD-1 (Nivolumab) in Advanced Refractory Solid Tumors
A Phase l/ll Dose Escalation and Cohort Expansion Study of the Safety, Tolerability and Efficacy of Anti-CD27 Antibody (Varlilumab) Administered in Combination With Anti-PD-1 (Nivolumab) in Advanced Refractory Solid Tumors
Enrollment Status: Completed
Publish Date: December 09, 2019
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
A Phase I A/B Study of the Folic Acid-Tubulysin Conjugate EC1456 In Patients With Advanced Solid Tumors
A Phase I A/B Study of the Folic Acid-Tubulysin Conjugate EC1456 In Patients With Advanced Solid Tumors
Enrollment Status: Completed
Publish Date: February 07, 2019
Intervention Type: Drug
Study Phase: Phase 1
An Intensive QT/QTc Study to Investigate the Effects of Rovalpituzumab Tesirine on Cardiac Ventricular Repolarization in Subjects With Small Cell Lung Cancer
An Intensive QT/QTc Study to Investigate the Effects of Rovalpituzumab Tesirine on Cardiac Ventricular Repolarization in Subjects With Small Cell Lung Cancer
Enrollment Status: Completed
Publish Date: September 24, 2018
Intervention Type: Drug
Study Phase: Phase 1
View 11 Less Clinical Trials

21 Total Publications

Safety, tolerability and efficacy of agonist anti-CD27 antibody (varlilumab) administered in combination with anti-PD-1 (nivolumab) in advanced solid tumors.
Safety, tolerability and efficacy of agonist anti-CD27 antibody (varlilumab) administered in combination with anti-PD-1 (nivolumab) in advanced solid tumors.
Journal: Journal for immunotherapy of cancer
Published: June 09, 2022
Similar Doctors
Advanced in Essential Thrombocythemia
Dr. Slobodan M. Stanisic
Hematology Oncology | Hematology | Oncology
Advanced in Essential Thrombocythemia
Dr. Slobodan M. Stanisic
Hematology Oncology | Hematology | Oncology

Christ Hospital Medical Specialists Ii, LLC

1955 Dixie Hwy, Suite G, 
Fort Wright, KY 
 (5.0 mi)
859-331-3304
Languages Spoken:
English, Bosnian, Croatian, Serbian, Sign Language
See accepted insurances
Accepting New Patients

Slobodan Stanisic is a Hematologist Oncology specialist and a Hematologist in Fort Wright, Kentucky. Dr. Stanisic and is rated as a Distinguished provider by MediFind in the treatment of Essential Thrombocythemia. His top areas of expertise are Leukocytosis, Familial Colorectal Cancer, Colorectal Cancer, Bone Marrow Aspiration, and Endoscopy. Dr. Stanisic is currently accepting new patients.

Advanced in Essential Thrombocythemia
Dr. Emmanuel A. Nidhiry
Oncology | Hematology Oncology | Hematology
Advanced in Essential Thrombocythemia
Dr. Emmanuel A. Nidhiry
Oncology | Hematology Oncology | Hematology

Norton - Kings Daughters Health Inc

1373 E State Rd, 62 Kings Daughters Health, 
Madison, IN 
 (51.3 mi)
812-801-0801
Languages Spoken:
English, Malayalam
See accepted insurances
Accepting New Patients

Emmanuel Nidhiry is an Oncologist and a Hematologist Oncology provider in Madison, Indiana. Dr. Nidhiry and is rated as a Distinguished provider by MediFind in the treatment of Essential Thrombocythemia. His top areas of expertise are Paget Disease of the Breast, Lung Cancer, Pleuropulmonary Blastoma, Familial Colorectal Cancer, and Bone Marrow Aspiration. Dr. Nidhiry is currently accepting new patients.

Advanced in Essential Thrombocythemia
Dr. Sulfikar F. Ibrahim
Hematology Oncology | Hematology | Oncology
Advanced in Essential Thrombocythemia
Dr. Sulfikar F. Ibrahim
Hematology Oncology | Hematology | Oncology

Reid Physician Associates Inc

1100 Reid Pkwy, 
Richmond, IN 
 (55.1 mi)
765-983-3122
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Sulfikar Ibrahim is a Hematologist Oncology specialist and a Hematologist in Richmond, Indiana. Dr. Ibrahim and is rated as a Distinguished provider by MediFind in the treatment of Essential Thrombocythemia. His top areas of expertise are Lung Adenocarcinoma, Small Cell Lung Cancer (SCLC), Familial Colorectal Cancer, and Lynch Syndrome. Dr. Ibrahim is currently accepting new patients.

Areas of Expertise

When evaluating expertise, MediFind pulls from factors such as the number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

To learn more about how MediFind determines the expertise levels, check out our expert tiers page.

Search for your specific condition
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile